Newron Pharmaceuticals S.p.A. (NWPHF)
| Market Cap | 386.89M +113.9% |
| Revenue (ttm) | 22.46M -62.8% |
| Net Income | -15.54M |
| EPS | -0.78 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 100 |
| Average Volume | 964 |
| Open | 12.00 |
| Previous Close | 11.40 |
| Day's Range | 12.00 - 12.00 |
| 52-Week Range | 5.22 - 12.00 |
| Beta | 0.72 |
| RSI | n/a |
| Earnings Date | Mar 24, 2026 |
About Newron Pharmaceuticals
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson’s in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company’s lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III cl... [Read more]
News
Newron Presents 2025 Financial Results and Provides 2026 Outlook
MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron today announced its financial results and operational highlights for the business year ended Dec. 31, 2025, and provided an o...
Newron to Present at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)
MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel th...
Newron Announces Agreement With the European Investment Bank (EIB) to Extend the Near-Term Tranche Repayment Dates of Its 2018 Finance Contract
MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 Finan...
Newron Announces Nominations to Its Board of Directors at Upcoming Annual General Meeting
MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron announces nominations to its Board of Directors at its upcoming Annual General Meeting.
Newron Secures Up to EUR 38 Million to Advance Phase III Evenamide Program
MILAN, Italy & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron secures up to EUR 38 million to advance Phase III Evenamide program as potential first add-on therapy for treatment-re...
Newron Notes Publication Highlighting Clinically Meaningful Benefits of Evenamide as an Adjunctive Treatment in Schizophrenia
MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron Pharmaceuticals notes new publication highlighting clinically meaningful benefits of evenamide as an adjunctive treatment in ...
EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan
MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron's partner EA Pharma Co., Ltd. announces today the initiation of its Phase III clinical trial with evenamide in Japan.
Newron Further Expands Intellectual Property Portfolio for Evenamide with New EU Composition of Matter Patent
MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron Pharmaceuticals further expands its intellectual property portfolio for Evenamide with a new EU composition of matter patent.
Newron to Host Investor and Partnering Meetings During the J.P. Morgan Healthcare Conference Week
MORRISTOWN, N.J. & MILAN--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron will host investor and partnering meetings on January 12-14, 2026, coinciding with the 44th Annual J.P. Morgan Conference in ...
Newron Announces the US Initiation of Its ENIGMA-TRS 2 Phase III Global Clinical Study With Evenamide as an Add-On Therapy for Patients With Treatment-Resistant Schizophrenia (TRS)
MORRISTOWN, N.J. & MILAN--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron announces US initiation of its ENIGMA-TRS 2 Phase III global study of evenamide for patients with treatment-resistant schizop...
Newron to Present New Analyses From and Updates on its Clinical Program Evaluating Evenamide as an Add-on Treatment for Schizophrenia at the 38th European College of Neuropsychopharmacology (ECNP) Congress 2025
MILAN--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron to present new analyses on its clinical program evaluating evenamide as an add-on treatment for schizophrenia at the ECNP Congress 2025.
Newron presents H1 2025 results and provides business update
MILAN--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron Pharmaceuticals today announced its financial results and operational highlights for the half-year ended June 30, 2025.
Newron to present data and updates on its clinical program evaluating evenamide as an add-on treatment for schizophrenia at the 2025 World Congress of Biological Psychiatry (WCBP)
MILAN--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron to present data on its clinical programs evaluating evenamide for schizophrenia at the 2025 World Congress of Biological Psychiatry (WCBP).
Newron Begins Enrollment in Pivotal Phase III ENIGMA-TRS Program With Evenamide as Add-on Therapy in Patients With Treatment-Resistant Schizophrenia (TRS)
MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron begins enrollment in pivotal Phase III ENIGMA-TRS program with evenamide as add-on therapy for treatment-resistant schizophre...
Newron Notes the Publication of New Preclinical Research Suggesting Evenamide Ameliorates Schizophrenia-Related Dysfunction
MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #schizophrenia--New findings in Neuropsychopharmacology - first to demonstrate that evenamide targets the key site of schizophrenia pathology in the...
Edison Issues Report on Newron Pharmaceuticals (NWRN)
London, United Kingdom--(Newsfile Corp. - July 9, 2025) - Edison issues report on Newron Pharmaceuticals (SIX: NWRN). Newron Pharmaceuticals is making significant headway in progressing its drug candi...
Newron Announces Approval for Pivotal Phase III ENIGMA-TRS Program With Evenamide as Add-on Therapy in Patients With Treatment-resistant Schizophrenia (TRS)
MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron initiates pivotal Phase III trial for evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS).
Newron Presents 2024 Financial Results and Provides 2025 Outlook
MILAN--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron presents 2024 financial results and provides 2025 outlook.
Newron Pharmaceuticals to Participate in a Fireside Chat at the 37th Annual ROTH Conference
MILAN, Italy & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron to participate in a fireside chat at the 37th Annual ROTH Conference on Monday, March 17 at 11:30 am PDT.
Newron and Myung In Pharm Announce License Agreement for evenamide in South Korea
MILAN, Italy & MORRISTOWN, New Jersey & SEOUL, Republic of Korea--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron and Myung In Pharm, South Korea's leading specialist CNS pharma company, announce lic...
Newron and EA Pharma (A Subsidiary of Eisai Co., Ltd.) Announce License Agreement for Evenamide in Japan and Other Asian Territories
MILAN & MORRISTOWN, N.J. & TOKYO--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron and EA Pharma sign licence for evenamide in Japan & Asia. Newron to receive up to €117 million from upfront payments,...
Newron presents H1 2024 results and provides business update
MILAN--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron today announces its financial and operational results for the half year ended June 30, 2024, and provides an update on its business activities.
Newron Pharmaceuticals Reports on Its 2024 Investor Day in New York City
MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron reports data from its 2024 Investor Day indicating evenamide would be uniquely effective in patients with treatment resistant...
Newron Pharmaceuticals 2024 Investor Day on June 25, 2024, in New York City
MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron Pharmaceuticals to host its 2024 Investor Day on June 25, 2024, in New York City. Live webcast beginning at 9:00 AM EDT.
Newron Pharmaceuticals Will Host Its 2024 Investor Day on June 25 in New York City
MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron Pharmaceuticals will host its 2024 Investor Day on June 25 in New York City. New hope emerges for treatment-resistant schizop...